Quantcast

Latest Vancomycin Stories

2010-03-15 07:00:00

HAYWARD, Calif. and SHANGHAI, March 15 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including...

2010-03-12 07:00:00

TAIPEI, Taiwan, March 12 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability. Nemonoxacin is a novel non-fluorinated quinolone that has a broad spectrum of activity against gram-positive and gram-negative bacteria and atypical pathogens. Importantly, nemonoxacin possesses activities...

2010-03-11 13:03:00

DURHAM, N.C., March 11 /PRNewswire/ -- bioMerieux - a world leader in the field of in vitro diagnostics - today announced the launch of the first Food and Drug Administration (FDA) cleared chromID(TM) VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID VRE is the first to receive an FDA 510(k) clearance for the qualitative detection of Enterococcus faecium and Enterococcus faecalis showing acquired resistance to vancomycin in...

2010-03-02 15:15:00

EXTON, Pa., March 2 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Cowen and Company 30th Annual Healthcare Conference at 11:05 A.M. ET on Tuesday, March 9, 2010. The conference is being held at the Boston Marriott Copley Place. ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days...

2010-02-17 15:00:00

EXTON, Pa., Feb. 17 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) fourth quarter and year end financial results for 2009 are expected to be released on Wednesday, February 24, 2010 before the open of the U.S. financial markets. The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2009 fourth quarter and full year financial results and other...

2010-01-11 06:31:00

EXTON, Pa., Jan. 11 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will provide an overview of the company's business and present a financial update during the 28th Annual J.P. Morgan Healthcare Conference. As previously announced, this presentation will be webcast live at 11:00 A.M. ET (8:00 A.M. PT) on Wednesday, January 13, 2010 and may be accessed via the company's website at...

2010-01-11 06:30:00

EXTON, Pa., Jan. 11 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that it has signed an agreement with Sanquin Blood Supply Foundation for rights to develop, file regulatory dossiers, and commercialize Cinryze(TM) (C1 esterase inhibitor [human]) for hereditary angioedema (HAE) as well as for potential new indications in certain European and rest of world (ROW) territories. This agreement significantly expands ViroPharma's rights to commercialize Cinryze...

2010-01-06 10:30:00

EXTON, Pa., Jan. 6 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the 28th Annual J.P. Morgan Healthcare Conference at 11:00 A.M. ET (8:00 A.M. PT) on Wednesday, January 13, 2010. The conference is being held at the Westin St. Francis Hotel in San Francisco. ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a...

2010-01-06 06:00:00

SUNNYVALE, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® vanA, the first rapid and accurate test released in the United States for vanA, the antimicrobial resistance gene most commonly associated with vancomycin-resistant enterococci (VRE) -- one of the more serious healthcare-associated infections (HAI). The 45-minute test runs on Cepheid's...

2009-12-10 07:00:00

WOBURN, Mass., and VEDBAEK, Denmark, Dec. 10 /PRNewswire/ -- AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its S. aureus PNA FISH® and S. aureus/CNS PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes. Clinical validation studies performed at hospitals in the United...


Latest Vancomycin Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »
Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.